Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA492694
Max Phase: Preclinical
Molecular Formula: C26H44N8O5
Molecular Weight: 548.69
Molecule Type: Small molecule
Associated Items:
ID: ALA492694
Max Phase: Preclinical
Molecular Formula: C26H44N8O5
Molecular Weight: 548.69
Molecule Type: Small molecule
Associated Items:
Synonyms (1): Phenacetyl Kkr-Acid
Synonyms from Alternative Forms(1):
Canonical SMILES: N=C(N)NCCC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)Cc1ccccc1)C(=O)O
Standard InChI: InChI=1S/C26H44N8O5/c27-14-6-4-11-19(32-22(35)17-18-9-2-1-3-10-18)23(36)33-20(12-5-7-15-28)24(37)34-21(25(38)39)13-8-16-31-26(29)30/h1-3,9-10,19-21H,4-8,11-17,27-28H2,(H,32,35)(H,33,36)(H,34,37)(H,38,39)(H4,29,30,31)/t19-,20-,21-/m0/s1
Standard InChI Key: XHVGUCXLWRVFJQ-ACRUOGEOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 548.69 | Molecular Weight (Monoisotopic): 548.3435 | AlogP: -0.71 | #Rotatable Bonds: 20 |
Polar Surface Area: 238.54 | Molecular Species: ZWITTERION | HBA: 7 | HBD: 9 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.74 | CX Basic pKa: 11.90 | CX LogP: -3.00 | CX LogD: -8.02 |
Aromatic Rings: 1 | Heavy Atoms: 39 | QED Weighted: 0.06 | Np Likeness Score: 0.10 |
1. Stoermer MJ, Chappell KJ, Liebscher S, Jensen CM, Gan CH, Gupta PK, Xu WJ, Young PR, Fairlie DP.. (2008) Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity., 51 (18): [PMID:18729351] [10.1021/jm800503y] |
2. Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM.. (2022) SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease., 57 [PMID:35123179] [10.1016/j.bmc.2022.116631] |
Source(1):